AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX)’s share price hit a new 52-week high during mid-day trading on Monday . The company traded as high as $5.48 and last traded at $5.50, with a volume of 3,010,064 shares traded. The stock had previously closed at $4.60.

ACRX has been the subject of several analyst reports. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of AcelRx Pharmaceuticals in a research report on Tuesday. Zacks Investment Research downgraded shares of AcelRx Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Roth Capital reiterated a “buy” rating and issued a $12.50 price target on shares of AcelRx Pharmaceuticals in a research report on Thursday, August 10th. ValuEngine raised shares of AcelRx Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Tuesday, September 26th. Finally, Jefferies Group LLC reissued a “buy” rating and set a $7.00 price objective on shares of AcelRx Pharmaceuticals in a research note on Friday, July 14th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $7.93.

The stock’s 50-day moving average price is $3.44 and its 200-day moving average price is $2.88. The firm’s market capitalization is $249.59 million.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last released its earnings results on Tuesday, August 1st. The specialty pharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.01). The company had revenue of $2.66 million for the quarter, compared to analyst estimates of $2.63 million. Equities analysts predict that AcelRx Pharmaceuticals, Inc. will post ($1.13) EPS for the current year.

In other AcelRx Pharmaceuticals news, insider Pamela P. Palmer bought 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 22nd. The shares were bought at an average price of $2.95 per share, for a total transaction of $29,500.00. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, insider Lawrence G. Hamel sold 10,161 shares of the company’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $5.29, for a total value of $53,751.69. Following the sale, the insider now owns 16,379 shares in the company, valued at approximately $86,644.91. The disclosure for this sale can be found here. Over the last three months, insiders bought 37,000 shares of company stock valued at $112,280. Corporate insiders own 28.10% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Teachers Advisors LLC increased its holdings in AcelRx Pharmaceuticals by 14.6% in the fourth quarter. Teachers Advisors LLC now owns 66,715 shares of the specialty pharmaceutical company’s stock worth $173,000 after purchasing an additional 8,475 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in AcelRx Pharmaceuticals by 6.6% in the first quarter. Bank of New York Mellon Corp now owns 112,682 shares of the specialty pharmaceutical company’s stock valued at $355,000 after buying an additional 6,942 shares during the period. Virtu KCG Holdings LLC lifted its stake in AcelRx Pharmaceuticals by 600.9% in the second quarter. Virtu KCG Holdings LLC now owns 118,675 shares of the specialty pharmaceutical company’s stock valued at $255,000 after buying an additional 101,742 shares during the period. LMR Partners LLP acquired a new position in AcelRx Pharmaceuticals in the second quarter valued at approximately $319,000. Finally, WealthTrust Axiom LLC lifted its stake in AcelRx Pharmaceuticals by 50.0% in the second quarter. WealthTrust Axiom LLC now owns 210,000 shares of the specialty pharmaceutical company’s stock valued at $451,000 after buying an additional 70,000 shares during the period. 23.32% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “AcelRx Pharmaceuticals, Inc. (ACRX) Hits New 1-Year High at $5.48” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/10/04/acelrx-pharmaceuticals-inc-acrx-hits-new-1-year-high-at-5-48.html.

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Receive News & Stock Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.